The researchers said that affordable tests that can differentiate malaria from similar diseases is vital for administering the most targeted treatment for patients.
The firm's CTO Sarah Levy said the Series C funding will enable it to expand R&D activities to develop applications beyond complete blood counts.
Researchers at Washington University in Saint Louis will use new funds to confirm preliminary findings on malaria-infected kids in a second location in Africa.
The company will provide 1 million rapid diagnostic tests, $750,000, and technical expertise as part of an effort in Odisha to eliminate the disease.
The firm is taking its in-home monitoring systems for COPD and cystic fibrosis, and its professional-use sepsis confirmation system through clinical trials.
To combat the challenge of counterfeit diagnostic tests, IBM scientists have developed a method to embed security codes to authenticate diagnostic tests.
Having achieved CE marking, the new OLO system has launched in Europe and non-US countries, while the company is conducting studies necessary for US FDA clearance.
The partners will further develop a test to guide clinical care of patients with Plasmodium vivax malaria who may also have G6PD deficiency.
To detect clinically relevant levels, the magneto-optic system measured magnetic nanocrystals in rabbit blood created by the malaria parasite.
The test will expand the range of diagnostic options available to guide treatment of Plasmodium vivax malaria, which relapses.